
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
This trial was for people with chronic myeloid leukaemia. It looked at adding a targeted drug to the targeted drug people were already taking.
It was open to people with chronic myeloid leukaemia (CML):
Cancer Research UK supported this trial.
When this trial was done, doctors could treat chronic myeloid leukaemia (CML) with one of the following:
These are cancer growth blockers called tyrosine kinase inhibitors (TKIs). Tyrosine kinase is a protein that acts as a messenger to stimulate cancer cells to grow. TKIs block these messages.
Sometimes these drugs stop working. So researchers were looking for other drugs to help people in this situation. In this trial, they are looked at other TKI's
The aims of this trial were to find out:
There aren't any results available for this trial. This was because it closed earlier than planned as it was difficult to recruit patients to take part.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Mhairi Copland
Cancer Research UK
University of Glasgow
NHS Greater Glasgow and Clyde
This is Cancer Research UK trial number CRUK/17/016.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.